Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04408794 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 974
- Enrollment target
NCT04408794 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 974 participants.
The verdict
NCT04408794, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 974 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant intranasal in the acute treatment of migraine. \* BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee revised the name to "zavegepant" which was accepted by the United States Adopted Names (USAN ) Council for use in the U.S. and is pending formal adoption by the INN for international use.
Interventions
- DRUG Zavegepant (BHV-3500)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 974 participants |
| Start Date | 2020-06-29 |
| Est. Completion | 2021-12-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04408794
The ClinicalTrials.gov registry entry for NCT04408794 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 974 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zavegepant (BHV-3500) is the first listed.
NCT04408794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04408794 about?
NCT04408794 is a clinical study titled "Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine". The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant intranasal in the acute treatment of migraine. \* BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The World Health Organization (WHO) International Nonproprietary Names (INN) E...
What is the current status of trial NCT04408794?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 974 participants. The study started on 2020-06-29. Estimated completion is 2021-12-23.
What interventions are being tested in trial NCT04408794?
The interventions under investigation include: Zavegepant (BHV-3500) (DRUG).
Who is sponsoring clinical trial NCT04408794?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.